Polaris Market Research today announced findings from its latest report, highlighting continued expansion in the global non-human primate pre-clinical studies at contract research organizations market. The market was valued at USD 39,546.55 thousand in 2022 and is projected to reach USD 108,553.86 thousand by 2032, expanding at a CAGR of 11.0% during the forecast period. The market covers applications including infectious disease, immunological disease, cancer, cardiovascular disease, metabolic diseases, genetic disease, respiratory diseases, neurological disease, female-related diseases, and others, across major geographic regions.

Key Growth Drivers, Major Companies and Segments Covered

Growth Drivers: Non-human primates are widely used in pre-clinical research because their behavioral, genetic, and physiological characteristics can provide relevant models for certain areas of human biomedical research. Increasing R&D activity related to vaccines, therapeutics, medical devices, and disease interventions is supporting demand for specialized pre-clinical studies. The rising prevalence of cancer, diabetes, cardiovascular disorders, infectious diseases, and other conditions is also increasing the need for research before human clinical trials.

Contract research organizations can provide specialized infrastructure and expertise for conducting these studies, supporting pharmaceutical and biotechnology companies that require outsourced research capabilities. The report also identifies innovations such as CRISPR technologies and growing demand associated with target diseases as factors supporting market development, while high procedure costs and regulatory complexities remain challenges.

Major Companies Covered:

• ABL, Inc.
• Applied BioCode Corporation
• BioLegend, Inc.
• Exocell, Inc.
• HUREL Corporation
• iQ Biosciences
• Mabtech AB

Segments Covered: By Application, the market is divided into Infectious Disease, Immunological Disease, Cancer, Cardiovascular Disease, Metabolic Diseases, Genetic Disease, Respiratory Diseases, Neurological Disease, Female Related Diseases, and Others. The geographic analysis covers North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Browse More Information:

https://www.polarismarketresearch.com/industry-analysis/non-human-primate-pre-clinical-studies-at-contract-research-organizations-market 

Market Dynamics and Segment Highlights

Infectious disease applications represented an important area of the market in 2022, supported by increased research requirements for vaccines and treatments for infectious conditions. The COVID-19 pandemic further highlighted the role of pre-clinical research in evaluating potential vaccines and therapies before advancing to human studies. At the same time, research activity in immunological disorders, cancer, cardiovascular diseases, metabolic conditions, and neurological diseases continues to contribute to demand.

North America recorded significant market penetration in 2022, supported by established healthcare and pharmaceutical infrastructure and the presence of major market participants. Asia Pacific is expected to experience strong growth during the forecast period, supported by increasing R&D activities in countries such as India and China.

Recent Developments

In March 2022, Applied BioCode announced an agreement with Hardy Diagnostics for distribution of the MDx-3000 System and related diagnostic offerings in the United States. The development expanded access to diagnostic technologies for several applications.

Regional Snapshot

North America held a significant position in 2022, while Asia Pacific is expected to register the highest CAGR during the forecast period. Increasing research activity, expanding pharmaceutical capabilities, and growing investment in biomedical development are expected to support the Asia Pacific market.

The COVID-19 pandemic disrupted NHP transportation, supplies, research operations, and laboratory activities. At the same time, CRO resources were redirected toward COVID-19 vaccine and therapeutic research, affecting other research programs and funding priorities. The market has subsequently continued to develop as pharmaceutical and biotechnology companies expand pre-clinical research requirements.

Why It Matters for Stakeholders

For pharmaceutical companies, biotechnology firms, CROs, investors, and research organizations, understanding the non-human primate pre-clinical studies market provides insight into changing outsourcing requirements, application demand, regional opportunities, and competitive activity. The report evaluates market dynamics, competitive conditions, regional trends, and application-level opportunities through 2032.

Conclusion

The non-human primate pre-clinical studies at contract research organizations market is gaining momentum as pharmaceutical and biotechnology research becomes increasingly focused on complex diseases and advanced therapies. With the market projected to reach USD 108,553.86 thousand by 2032 at an 11.0% CAGR, expanding biomedical R&D, demand for specialized CRO capabilities, and increasing research activity across Asia Pacific are expected to remain important factors shaping the market.

More Trending Latest Reports By Polaris Market Research:

Solar Tracker Market

Geriatric Medicines Market

Electric Tile Cutter Market

Genomics In Cancer Care Market

Pad-mounted Switchgear Market

Hereditary Testing Market

Hereditary Testing Market

Electric Tile Cutter Market

EV Solar Modules Market